Skip to main content

Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN · Delayed Price · USD
2.51
-0.09 (-3.46%)
Pre-market:Sep 20, 2021 7:19 AM EDT
2.60
-0.07 (-2.62%)
At close: Sep 17, 4:00 PM
Market Cap225.91M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out84.59M
EPS (ttm)-0.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume526,023
Open2.74
Previous Close2.67
Day's Range2.55 - 2.74
52-Week Range2.50 - 33.55
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About ALZN

Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Our primary target is Alzheimer’s disease. Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans...

IndustryBiotechnology
IPO DateJun 15, 2021
CEOStephan Jackman
Employees2
Stock ExchangeNASDAQ
Ticker SymbolALZN
Full Company Profile

Financial Performance

Financial Statements

News

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzhei...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Initiates Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease; Doses First Participant Group

1 week ago - Business Wire

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia ...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Additional $2M Investment from Digital Power Lending Due to Its IND Application for AL001 for Dementia Related to Alzheimers

1 month ago - Business Wire

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the A...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits Pre-IND for AL002 as Therapeutic Vaccine That Seeks to Restore Ability of Patient's Immunological System to Combat Alzheimer's

1 month ago - Business Wire

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug ...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives FDA “Study May Proceed” Letter for AL001 Phase 1 Clinical Study Investigational New Drug Application for Alzheimer's Disease

1 month ago - Business Wire

Why Alzamend Neuro Stock Fell More Than 14% Today

Investors have been driving it lower for over a month now, but the stock just reached a curious price level.

1 month ago - The Motley Fool

Here's Why Alzamend Neuro Stock Is Shooting Higher Today

There's never been a better time to be a mouse with Alzheimer's disease.

1 month ago - The Motley Fool

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Inc (NASDAQ: ALZN) has announced positive toxicology results for AL002 in a toxicology study using a transgenic mouse model of Alzheimer's disease.  Charles River Laboratories conducted t...

1 month ago - Benzinga

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

TAMPA, Fla.--(BUSINESS WIRE)---- $ALZN #505b2--Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today at 9:15am ET; Alzamend Celebrates Successful Initial Public Offering and Corporate Milestone

2 months ago - Business Wire

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Ault Global Holdings Inc (NYSE: DPW), a diversified holding company, has announced that Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug application to the FDA for a Phase 1 s...

2 months ago - Benzinga

Why Alzamend Neuro Stock Popped Today

There wasn't an obvious catalyst for this recent IPO stock.

2 months ago - The Motley Fool

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option ...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Closing of Initial Public Offering & Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

3 months ago - Business Wire

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

LAS VEGAS--(BUSINESS WIRE)---- $AGH #AP--Ault Global Holdings Announces Alzamend Neuro (Nasdaq: ALZN) Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock at $5.00 per Share

Other symbols:DPW
3 months ago - Business Wire

Alzamend Neuro Announces Pricing of Initial Public Offering

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Pricing of Initial Public Offering of 2,500,000 Shares of its Common Stock at a Price to the Public of $5.00 per Share

3 months ago - Business Wire

Alzamend Neuro IPO Registration Document (S-1)

Alzamend Neuro, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC